AR127165A1 - Resmetirom para reducir el volumen del hígado - Google Patents
Resmetirom para reducir el volumen del hígadoInfo
- Publication number
- AR127165A1 AR127165A1 ARP220102600A ARP220102600A AR127165A1 AR 127165 A1 AR127165 A1 AR 127165A1 AR P220102600 A ARP220102600 A AR P220102600A AR P220102600 A ARP220102600 A AR P220102600A AR 127165 A1 AR127165 A1 AR 127165A1
- Authority
- AR
- Argentina
- Prior art keywords
- resmetirom
- liver volume
- reduce liver
- prodrug
- subject
- Prior art date
Links
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 title abstract 4
- 229940121486 resmetirom Drugs 0.000 title abstract 4
- 210000004185 liver Anatomy 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248634P | 2021-09-27 | 2021-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127165A1 true AR127165A1 (es) | 2023-12-27 |
Family
ID=83900064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102600A AR127165A1 (es) | 2021-09-27 | 2022-09-27 | Resmetirom para reducir el volumen del hígado |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20240408102A1 (enExample) |
| EP (2) | EP4578499A3 (enExample) |
| JP (1) | JP2024536126A (enExample) |
| KR (1) | KR20240073926A (enExample) |
| CN (1) | CN118251221A (enExample) |
| AR (1) | AR127165A1 (enExample) |
| AU (1) | AU2022348966A1 (enExample) |
| CA (1) | CA3233319A1 (enExample) |
| CL (1) | CL2024000886A1 (enExample) |
| IL (1) | IL311670A (enExample) |
| MX (1) | MX2024003967A (enExample) |
| TW (1) | TW202337470A (enExample) |
| WO (1) | WO2023049491A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024251233A1 (zh) * | 2023-06-08 | 2024-12-12 | 成都微芯药业有限公司 | PPAR全激动剂联合THR-β激动剂在抗代谢相关疾病中的用途 |
| JP2026521649A (ja) * | 2023-06-22 | 2026-06-30 | マドリガル ファーマシューティカルズ インコーポレイテッド | ＴＨＲ－βアゴニストを用いて肝障害を治療するためのバイオマーカーおよび関連する使用 |
| KR20260000642A (ko) * | 2024-06-25 | 2026-01-05 | 연세대학교 산학협력단 | Usp10 억제제를 유효성분으로 포함하는, 간섬유증 또는 간섬유증 관련 질환의 예방 또는 치료용 조성물 |
| WO2026107045A1 (en) * | 2024-11-12 | 2026-05-21 | Madrigal Pharmaceuticals, Inc. | Resmetirom for use in treating cardiomyopathy and/or related heart failure and portal hypertension |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE480524T1 (de) | 2005-07-21 | 2010-09-15 | Hoffmann La Roche | Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten |
| US8076334B2 (en) | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| ES2795450T3 (es) | 2012-09-17 | 2020-11-23 | Madrigal Pharmaceuticals Inc | Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos |
| MX394463B (es) | 2016-10-18 | 2025-03-19 | Madrigal Pharmaceuticals Inc | Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta. |
| TW202615431A (zh) | 2018-07-02 | 2026-04-16 | 美商瑪德瑞高製藥公司 | ２－（３，５－二氯－４－（（５－異丙基－６－側氧基－１，６－二氫噠嗪－３－基）氧）苯基）－３，５－二側氧基－２，３，４，５－四氫－１，２，４－三嗪－６－腈之固體型式 |
| CA3111025C (en) * | 2018-09-06 | 2023-10-31 | Galmed Research And Development Ltd | Combination therapy for the treatment of liver disease |
| EP4775207A2 (en) | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| CA3195960A1 (en) | 2020-10-23 | 2022-04-28 | Madrigal Pharmaceuticals, Inc. | Process for the preparation of 6-(4-nitro-phenoxy)-2h-pyridazin-3-one and 6-(4-amino-phenoxy)-2h-pyridazin-3-one derivatives as intermediates of thyroid hormone analogues |
-
2022
- 2022-09-27 TW TW111136510A patent/TW202337470A/zh unknown
- 2022-09-27 IL IL311670A patent/IL311670A/en unknown
- 2022-09-27 EP EP24212126.7A patent/EP4578499A3/en active Pending
- 2022-09-27 MX MX2024003967A patent/MX2024003967A/es unknown
- 2022-09-27 US US18/695,572 patent/US20240408102A1/en active Pending
- 2022-09-27 CN CN202280075697.1A patent/CN118251221A/zh active Pending
- 2022-09-27 EP EP22793025.2A patent/EP4408428A1/en not_active Withdrawn
- 2022-09-27 JP JP2024519112A patent/JP2024536126A/ja active Pending
- 2022-09-27 CA CA3233319A patent/CA3233319A1/en active Pending
- 2022-09-27 AR ARP220102600A patent/AR127165A1/es unknown
- 2022-09-27 KR KR1020247013928A patent/KR20240073926A/ko active Pending
- 2022-09-27 WO PCT/US2022/044826 patent/WO2023049491A1/en not_active Ceased
- 2022-09-27 AU AU2022348966A patent/AU2022348966A1/en active Pending
-
2024
- 2024-03-26 CL CL2024000886A patent/CL2024000886A1/es unknown
-
2025
- 2025-11-12 US US19/386,839 patent/US12661361B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20260069598A1 (en) | 2026-03-12 |
| IL311670A (en) | 2024-05-01 |
| JP2024536126A (ja) | 2024-10-04 |
| MX2024003967A (es) | 2024-06-03 |
| US12661361B2 (en) | 2026-06-23 |
| AU2022348966A1 (en) | 2024-04-11 |
| US20240408102A1 (en) | 2024-12-12 |
| CN118251221A (zh) | 2024-06-25 |
| EP4408428A1 (en) | 2024-08-07 |
| CL2024000886A1 (es) | 2024-08-30 |
| KR20240073926A (ko) | 2024-05-27 |
| WO2023049491A1 (en) | 2023-03-30 |
| CA3233319A1 (en) | 2023-03-30 |
| EP4578499A2 (en) | 2025-07-02 |
| TW202337470A (zh) | 2023-10-01 |
| EP4578499A3 (en) | 2025-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240881A1 (es) | Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t | |
| CO2023001407A2 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| MX2022007350A (es) | Derivados de pirazolilo utiles como agentes anticancerigenos. | |
| CL2023003223A1 (es) | Derivado de fosfonilo, y composición y aplicación farmacéutica de este | |
| MX356176B (es) | Metodos para usar moduladores de c-met. | |
| UY37998A (es) | Agentes antivirales contra la hepatitis b | |
| UY39027A (es) | Uso de favipiravir en el tratamiento de la infección por coronavirus | |
| AR077629A1 (es) | Mimetico de smac | |
| MX2009001660A (es) | Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis. | |
| MX2025000273A (es) | Compuesto que contiene nitrogeno y uso del mismo | |
| MX2021009439A (es) | Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7. | |
| MX2024012930A (es) | Derivado de ester de ciclopentanol sustituido con pirazol y uso del mismo | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| CL2024000886A1 (es) | Resmetirom para reducir el volumen del hígado | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| DOP2025000146A (es) | Compuesto quimérico protac, método de preparación del mismo y uso del mismo | |
| AR062393A1 (es) | Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor | |
| CL2022000725A1 (es) | Inhibidor de irak y método de preparación para el mismo y uso del mismo | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| AR128100A1 (es) | Compuestos para el tratamiento de la pérdida del cabello | |
| CO2023017669A2 (es) | Terapia combinada anti-vhc ventajosa | |
| CL2025002792A1 (es) | Compuesto y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores | |
| AR126552A1 (es) | Composición farmacéutica para prevenir o tratar la esclerosis sistémica | |
| MX2022005199A (es) | Inhibidores de ssao y uso de los mismos. |